Conference Call Schedules, Presentations, Collaborations and FDA Approvals - Research Report on Pharmacyclics, Pacira Pharmaceuticals, Raptor Pharmaceuticals, Impax Laboratories, and AcelRx
Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pharmacyclics Inc. (NASDAQ: PCYC), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), Impax Laboratories Inc. (NASDAQ: IPXL), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pharmacyclics Inc. Research Report

On November 1, 2013, Pharmacyclics Inc. (Pharmacyclics) announced that it will host a conference call and audio webcast on Thursday, November 7, 2013, at 4:30 p.m. ET, to discuss its Q3 2013 financial results and recent developments. According to the Company, a replay of the webcast will also be available on Pharmacyclics' website for 30 days. The Full Research Report on Pharmacyclics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/df74_PCYC]

--

Pacira Pharmaceuticals Inc. Research Report

On November 1, 2013, Pacira Pharmaceuticals Inc. (Pacira Pharmaceuticals) announced that its President, CEO and Chairman, Dave Stack will present an overview of the Company at two investor conferences during November 2013. Pacira Pharmaceuticals informed that Mr. Stack's presentation at the Goldman Sachs US Emerging / SMID Cap Growth Conference is scheduled on Thursday, November 14, 2013, at 2:40 p.m. ET in New York. Meanwhile, Mr. Stack will also present the Company at the Jefferies 2013 Global Healthcare Conference on Thursday, November 21, 2013, at 9:20 a.m. BST or 4:20 a.m. ET in London, UK. According to the Company, a live audio webcast of the aforementioned presentations can be accessed through the investor & media section at Pacira Pharmaceuticals' website. The Full Research Report on Pacira Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/c0aa_PCRX]

--

Raptor Pharmaceuticals Corp. Research Report

On October 23, 2013, Raptor Pharmaceuticals Corp. (Raptor Pharmaceuticals) announced that it has collaborated with DaVita Clinical Research® (DCR) to screen blood samples from patients with end-stage renal disease (ESRD) in an effort to identify patients with unrecognized late-onset nephropathic cystinosis. According to the Company, DCR will supply blood samples with clinical data annotation from its biorepository of over four thousand patients with ESRD. Commenting on the new collaboration, Raptor Pharmaceuticals' CEO, Christopher M. Starr, Ph. D. stated, "Today, most nephropathic cystinosis patients are identified in infancy by pediatric nephrologists, yet, as with many genetic diseases, later-onset patients have been identified where the clinical manifestations of cystinosis may go unrecognized well into adulthood. We believe these late-onset patients are likely to present with ESRD as adults and this screening program, initiated with this collaboration, may help adult nephrologists, many of whom are unfamiliar with the late onset form of the disease, identify patients who suffer from cystinosis." The Full Research Report on Raptor Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/a001_RPTP]

--

Impax Laboratories Inc. Research Report  

On October 30, 2013, Impax Laboratories Inc. (Impax Laboratories) and TOLMAR, Inc. jointly announced the receipt of final FDA approval for Generic Solaraze® Gel. According to the Company, the US Food and Drug Administration (FDA) has granted final approval of TOLMAR's Abbreviated New Drug Application (ANDA) for its generic version of Solaraze® Gel (diclofenac sodium - 3%). The two companies further informed that TOLMAR was the first company to file a substantially complete ANDA containing a Paragraph IV certification, and Impax's generics division, Global Pharmaceuticals, intends to commercialize this first-to-file product shortly. According to Impax Laboratories, under a Development, Supply, and Distribution Agreement between the duos, TOLMAR, Inc. granted the Company an exclusive license to commercialize generic Solaraze in the US and its territories, while the former was responsible for developing and manufacturing the product. The Full Research Report on Impax Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4c54_IPXL]

--

AcelRx Pharmaceuticals, Inc. Research Report

On October 15, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced the presentations of its previously reported Phase 3 data for Zalviso™ (sufentanil sublingual microtablet system) at several major medical meetings in Europe and the US. According to the Company, AcelRx presented data from the Phase 3 clinical trial conducted in orthopedic surgery patients at the European Federation of IASP Chapters (EFIC) Annual Congress from October 9 - 12, 2013, in Florence, Italy and at the American Society of Anesthesiologists (ASA) meeting from October 12 - 16, 2013, in San Francisco. Richard King, President and CEO of AcelRx commented, "Presentations at important medical meetings in both the EU and US of favorable Phase 3 data for Zalviso represent an opportunity for investigators to discuss the trials and their impressions of Zalviso with other thought leaders in the pain-treatment community. Presentations of this data are an important step in the familiarization of the medical community with Zalviso, and in enabling early understanding of the potential value the product may provide to their patients, if approved by the regulatory agencies." The Full Research Report on AcelRx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/1454_ACRX]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


AnalystsCorner.com

SOURCE Analysts' Corner

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here